PRODUCTS

OUR PRODUCTS

CSL Seqirus markets and distributes a number of vaccines and pharmaceutical products to ensure a comprehensive range of products are available to the New Zealand market.

Information on our products is intended for use by New Zealanders:

Healthcare professionals who want to know more about a CSL Seqirus product,
and individuals who have been prescribed a CSL Seqirus product

Influenza

AFLURIA® Quad | Inactivated Quadrivalent Influenza vaccine (split virion)

AFLURIA® Quad Junior | Inactivated Quadrivalent Influenza vaccine (split virion)

FLUAD® Quad | Inactivated Influenza Vaccine, Adjuvanted

FLUCELVAX® Quad | Inactivated, Quadrivalent Influenza Vaccine, cell culture

In-Licensed Products

BCG VACCINE AJV™ | Live attenuated Mycobacterium bovis BCG (Bacillus Calmette-Guerin) vaccine

DUKORAL® | Oral inactivated cholera vaccine

For prevention of cholera and of travellers’ diarrhoea caused by serogroup O1 Vibrio cholera and heat-labile toxin-producing enterotoxigenic Escherichia coli (ETEC).

Data Sheet

Consumer Medicine Information

DUKORAL® is a registered trademark of Valneva Sweden AB.

GARDASIL® 9 | Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant

In women aged 9-45 years, for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 45, 52 and 58. In men aged 9-26 years for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

Data Sheet

Consumer Medicine Information

GARDASIL® 9 is a registered trademark of Merck Sharp & Dohme Corp.

JESPECT® | Inactivated Japanese Encephalitis vaccine

RABIPUR® | Inactivated Rabies Virus vaccine

For active immunisation against rabies virus, including (a) pre-exposure immunisation and (b) post-exposure treatment following exposure to rabies virus.

Data Sheet

Consumer Medicine Information

RABIPUR® is a registered trademark of Bavarian Nordic A/S.

TRAMAL® | Tramadol Hydrochloride

VIMPAT® | Lacosamide

Monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.

Data Sheet (Tablets and Oral solution)

Data Sheet (Injection)

Consumer Medicine Information (Tablets and Oral solution)

Consumer Medicine Information (Injection)

VIMPAT® is registered to HARRIS FRC Acquisition LP.

_{BCG VACCINE AJV™ is a trademark of AJ Vaccines A/S.

DUKORAL® and JESPECT® are registered trademarks of Valneva Sweden AB.

GARDASIL® 9 is a registered trademark of Merck & Co. Inc Whitehouse Station, NJ, USA.

RABIPUR® is a registered trademark of Bavarian Nordic A/S.

TRAMAL® is a registered trademark of Grunenthal GmbH used by Seqirus as authorised user.

VIMPAT® is a registered trademark used by UCB Pharma GmbH under license.

All other trademarks are registered by Seqirus UK Limited or its affiliates in one or more jurisdictions.}

Pandemic Response Solutions

As a global leader in influenza vaccine manufacturing, CSL Seqirus offers a portfolio of pandemic vaccines and services which are tailored to rapid response.
Learn more

globe

Report a Side Effect

If you have encountered any side effect(s) to a CSL Seqirus product, we encourage you to talk to your doctor, pharmacist, or nurse. CSL Seqirus also collects information about side effects in order to monitor product safety and investigate, evaluate and report undesirable events to appropriate regulatory bodies. To report a suspected side effect or adverse event, please visit our Report an Adverse Event page.

Learn more

AP-CRP-23-0001